Icahn Sues Amylin For Docs On Rebuffed $3.5B Bristol Bid

Law360, Wilmington (April 12, 2012, 4:24 PM EDT) -- Activist investor Carl Icahn stepped up his pressure Thursday on Amylin Pharmaceuticals Inc. over the company's alleged rejection of a $3.5 billion offer from Bristol-Myers Squibb Co., filing suit to force the drugmaker to open its books and records to shareholders.

On Wednesday, Amylin “flatly refused” a so-called Section 220 demand to voluntarily turn over records related to Bristol Myers’ February offer — along with documents on a subsequent grant of stock options and a public offering allegedly priced well below that bid, Icahn Partners LP...
To view the full article, register now.